Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer

In February 2005, Gefitinib （Iressa）, a small-molecular .epidermal growth factor receptor and tyrosine kinaseinhibitor, was approved in China as an anticancer agent for patients with advanced （local or metastatic） non-small cell lung cancer （NSCLC）, who failed prior chemotherapy. The common adverse...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2010-02, Vol.123 (4), p.505-506
Main Authors: Yuan, Guang-jin, Ke, Qin-hua, Xu, Xi-ming, Yang, Ji-yuan, Su, Xiao-yan
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Disseminated Intravascular Coagulation - chemically induced
Female
Humans
Quinazolines - adverse effects
Quinazolines - therapeutic use
不良反应
严重程度
皮肤瘙痒
血管内凝血
表皮生长因子受体
非小细胞肺癌
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 506
container_issue 4
container_start_page 505
container_title Chinese medical journal
container_volume 123
creator Yuan, Guang-jin
Ke, Qin-hua
Xu, Xi-ming
Yang, Ji-yuan
Su, Xiao-yan
description In February 2005, Gefitinib （Iressa）, a small-molecular .epidermal growth factor receptor and tyrosine kinaseinhibitor, was approved in China as an anticancer agent for patients with advanced （local or metastatic） non-small cell lung cancer （NSCLC）, who failed prior chemotherapy. The common adverse events of the drug include acne-like skin rash, paronychia, pruritus, diarrhea, nausea/vomiting, anorexia, hepatitis, and hyperbilirubinemia.1 However, these adverse events are generally mild in severity and reversible on cessation of the treatment. Therefore, gefitinib has been regarded as a relatively safe agent,
doi_str_mv 10.3760/cma.j.issn.0366-6999.2010.04.022
format article
fullrecord <record><control><sourceid>wanfang_jour_proqu</sourceid><recordid>TN_cdi_wanfang_journals_zhcmj201004022</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>33010623</cqvip_id><wanfj_id>zhcmj201004022</wanfj_id><sourcerecordid>zhcmj201004022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c268t-18cd6c74153c09967fa0cd01f0473139f349eb5c704f6644587ce735d837d99c3</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqXwCyhiAWwSHD_jJaqgIFViA-vImTipS-K0cUIFX4-rFjbz0Jy5M7oI3ac4oVLgB2h1sk6s9y7BVIhYKKUSgsMYswQTcoKmhDMSc8HSUzT9Zybowvs1xoRzKc7RJKwoyhSfIrMwlR2ss0VsXTmCKaMy6JvWOj2Exrqh11_aw9joPoJO16EYbOfCJNLRJtTGDdHODqvIdS72rW6aCEwIzejqCLQD01-is0o33lwd8wx9PD-9z1_i5dvidf64jIGIbIjTDEoBkqWcAlZKyEpjKHFaYSZpSlUVfjYFB4lZJQRjPJNgJOVlRmWpFNAZuj3o7rSrtKvzdTf2LlzMf1bQrvdOYRZ8CuDdAdz03XY0fshb6_dfa2e60eeSUpwJwvfk9ZEci9aU-aa3re6_8z8LA3BzAGDVuXprw9VCw2dlG5MHlRQLQukvb5KC-A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733086252</pqid></control><display><type>article</type><title>Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer</title><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><creator>Yuan, Guang-jin ; Ke, Qin-hua ; Xu, Xi-ming ; Yang, Ji-yuan ; Su, Xiao-yan</creator><creatorcontrib>Yuan, Guang-jin ; Ke, Qin-hua ; Xu, Xi-ming ; Yang, Ji-yuan ; Su, Xiao-yan</creatorcontrib><description>In February 2005, Gefitinib （Iressa）, a small-molecular .epidermal growth factor receptor and tyrosine kinaseinhibitor, was approved in China as an anticancer agent for patients with advanced （local or metastatic） non-small cell lung cancer （NSCLC）, who failed prior chemotherapy. The common adverse events of the drug include acne-like skin rash, paronychia, pruritus, diarrhea, nausea/vomiting, anorexia, hepatitis, and hyperbilirubinemia.1 However, these adverse events are generally mild in severity and reversible on cessation of the treatment. Therefore, gefitinib has been regarded as a relatively safe agent,</description><identifier>ISSN: 0366-6999</identifier><identifier>EISSN: 2542-5641</identifier><identifier>DOI: 10.3760/cma.j.issn.0366-6999.2010.04.022</identifier><identifier>PMID: 20193495</identifier><language>eng</language><publisher>China: Cancer Center, 82nd Hospital of the Chinese People's Liberation Army, Huai'an, Jiangsu 223001, China%Department of Oncology, First People's Hospital of Jingzhou,Jingzhou, Hubei 434000, China%Cancer Center, Renmin Hospital of Wuhan University, Wuhan,Hubei 430060, China</publisher><subject>Aged ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Disseminated Intravascular Coagulation - chemically induced ; Female ; Humans ; Quinazolines - adverse effects ; Quinazolines - therapeutic use ; 不良反应 ; 严重程度 ; 皮肤瘙痒 ; 血管内凝血 ; 表皮生长因子受体 ; 非小细胞肺癌</subject><ispartof>Chinese medical journal, 2010-02, Vol.123 (4), p.505-506</ispartof><rights>Copyright © Wanfang Data Co. Ltd. All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/85656X/85656X.jpg</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20193495$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yuan, Guang-jin</creatorcontrib><creatorcontrib>Ke, Qin-hua</creatorcontrib><creatorcontrib>Xu, Xi-ming</creatorcontrib><creatorcontrib>Yang, Ji-yuan</creatorcontrib><creatorcontrib>Su, Xiao-yan</creatorcontrib><title>Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer</title><title>Chinese medical journal</title><addtitle>Chinese Medical Journal</addtitle><description>In February 2005, Gefitinib （Iressa）, a small-molecular .epidermal growth factor receptor and tyrosine kinaseinhibitor, was approved in China as an anticancer agent for patients with advanced （local or metastatic） non-small cell lung cancer （NSCLC）, who failed prior chemotherapy. The common adverse events of the drug include acne-like skin rash, paronychia, pruritus, diarrhea, nausea/vomiting, anorexia, hepatitis, and hyperbilirubinemia.1 However, these adverse events are generally mild in severity and reversible on cessation of the treatment. Therefore, gefitinib has been regarded as a relatively safe agent,</description><subject>Aged</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Disseminated Intravascular Coagulation - chemically induced</subject><subject>Female</subject><subject>Humans</subject><subject>Quinazolines - adverse effects</subject><subject>Quinazolines - therapeutic use</subject><subject>不良反应</subject><subject>严重程度</subject><subject>皮肤瘙痒</subject><subject>血管内凝血</subject><subject>表皮生长因子受体</subject><subject>非小细胞肺癌</subject><issn>0366-6999</issn><issn>2542-5641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNo9kMtOwzAQRS0EoqXwCyhiAWwSHD_jJaqgIFViA-vImTipS-K0cUIFX4-rFjbz0Jy5M7oI3ac4oVLgB2h1sk6s9y7BVIhYKKUSgsMYswQTcoKmhDMSc8HSUzT9Zybowvs1xoRzKc7RJKwoyhSfIrMwlR2ss0VsXTmCKaMy6JvWOj2Exrqh11_aw9joPoJO16EYbOfCJNLRJtTGDdHODqvIdS72rW6aCEwIzejqCLQD01-is0o33lwd8wx9PD-9z1_i5dvidf64jIGIbIjTDEoBkqWcAlZKyEpjKHFaYSZpSlUVfjYFB4lZJQRjPJNgJOVlRmWpFNAZuj3o7rSrtKvzdTf2LlzMf1bQrvdOYRZ8CuDdAdz03XY0fshb6_dfa2e60eeSUpwJwvfk9ZEci9aU-aa3re6_8z8LA3BzAGDVuXprw9VCw2dlG5MHlRQLQukvb5KC-A</recordid><startdate>20100220</startdate><enddate>20100220</enddate><creator>Yuan, Guang-jin</creator><creator>Ke, Qin-hua</creator><creator>Xu, Xi-ming</creator><creator>Yang, Ji-yuan</creator><creator>Su, Xiao-yan</creator><general>Cancer Center, 82nd Hospital of the Chinese People's Liberation Army, Huai'an, Jiangsu 223001, China%Department of Oncology, First People's Hospital of Jingzhou,Jingzhou, Hubei 434000, China%Cancer Center, Renmin Hospital of Wuhan University, Wuhan,Hubei 430060, China</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W95</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope><scope>2B.</scope><scope>4A8</scope><scope>92I</scope><scope>93N</scope><scope>PSX</scope><scope>TCJ</scope></search><sort><creationdate>20100220</creationdate><title>Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer</title><author>Yuan, Guang-jin ; Ke, Qin-hua ; Xu, Xi-ming ; Yang, Ji-yuan ; Su, Xiao-yan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c268t-18cd6c74153c09967fa0cd01f0473139f349eb5c704f6644587ce735d837d99c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Disseminated Intravascular Coagulation - chemically induced</topic><topic>Female</topic><topic>Humans</topic><topic>Quinazolines - adverse effects</topic><topic>Quinazolines - therapeutic use</topic><topic>不良反应</topic><topic>严重程度</topic><topic>皮肤瘙痒</topic><topic>血管内凝血</topic><topic>表皮生长因子受体</topic><topic>非小细胞肺癌</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yuan, Guang-jin</creatorcontrib><creatorcontrib>Ke, Qin-hua</creatorcontrib><creatorcontrib>Xu, Xi-ming</creatorcontrib><creatorcontrib>Yang, Ji-yuan</creatorcontrib><creatorcontrib>Su, Xiao-yan</creatorcontrib><collection>维普_期刊</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>维普中文期刊数据库</collection><collection>中文科技期刊数据库-农业科学</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><collection>Wanfang Data Journals - Hong Kong</collection><collection>WANFANG Data Centre</collection><collection>Wanfang Data Journals</collection><collection>万方数据期刊 - 香港版</collection><collection>China Online Journals (COJ)</collection><collection>China Online Journals (COJ)</collection><jtitle>Chinese medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yuan, Guang-jin</au><au>Ke, Qin-hua</au><au>Xu, Xi-ming</au><au>Yang, Ji-yuan</au><au>Su, Xiao-yan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer</atitle><jtitle>Chinese medical journal</jtitle><addtitle>Chinese Medical Journal</addtitle><date>2010-02-20</date><risdate>2010</risdate><volume>123</volume><issue>4</issue><spage>505</spage><epage>506</epage><pages>505-506</pages><issn>0366-6999</issn><eissn>2542-5641</eissn><abstract>In February 2005, Gefitinib （Iressa）, a small-molecular .epidermal growth factor receptor and tyrosine kinaseinhibitor, was approved in China as an anticancer agent for patients with advanced （local or metastatic） non-small cell lung cancer （NSCLC）, who failed prior chemotherapy. The common adverse events of the drug include acne-like skin rash, paronychia, pruritus, diarrhea, nausea/vomiting, anorexia, hepatitis, and hyperbilirubinemia.1 However, these adverse events are generally mild in severity and reversible on cessation of the treatment. Therefore, gefitinib has been regarded as a relatively safe agent,</abstract><cop>China</cop><pub>Cancer Center, 82nd Hospital of the Chinese People's Liberation Army, Huai'an, Jiangsu 223001, China%Department of Oncology, First People's Hospital of Jingzhou,Jingzhou, Hubei 434000, China%Cancer Center, Renmin Hospital of Wuhan University, Wuhan,Hubei 430060, China</pub><pmid>20193495</pmid><doi>10.3760/cma.j.issn.0366-6999.2010.04.022</doi><tpages>2</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0366-6999
ispartof Chinese medical journal, 2010-02, Vol.123 (4), p.505-506
issn 0366-6999
2542-5641
language eng
recordid cdi_wanfang_journals_zhcmj201004022
source HEAL-Link subscriptions: Lippincott Williams & Wilkins
subjects Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Disseminated Intravascular Coagulation - chemically induced
Female
Humans
Quinazolines - adverse effects
Quinazolines - therapeutic use
不良反应
严重程度
皮肤瘙痒
血管内凝血
表皮生长因子受体
非小细胞肺癌
title Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T17%3A27%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wanfang_jour_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gefitinib-induced%20disseminated%20intravascular%20coagulation%20in%20a%20patient%20with%20non-small%20cell%20lung%20cancer&rft.jtitle=Chinese%20medical%20journal&rft.au=Yuan,%20Guang-jin&rft.date=2010-02-20&rft.volume=123&rft.issue=4&rft.spage=505&rft.epage=506&rft.pages=505-506&rft.issn=0366-6999&rft.eissn=2542-5641&rft_id=info:doi/10.3760/cma.j.issn.0366-6999.2010.04.022&rft_dat=%3Cwanfang_jour_proqu%3Ezhcmj201004022%3C/wanfang_jour_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c268t-18cd6c74153c09967fa0cd01f0473139f349eb5c704f6644587ce735d837d99c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733086252&rft_id=info:pmid/20193495&rft_cqvip_id=33010623&rft_wanfj_id=zhcmj201004022&rfr_iscdi=true